Canada markets open in 7 hours 49 minutes

Recce Pharmaceuticals Ltd (RCE.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.5950+0.0150 (+2.59%)
As of 03:20PM AEST. Market open.
Full screen
Previous Close0.5800
Open0.5800
Bid0.5850 x 55200
Ask0.5950 x 1644700
Day's Range0.5700 - 0.5950
52 Week Range0.4100 - 0.7772
Volume126,305
Avg. Volume155,775
Market Cap121.372M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings DateJul 29, 2024 - Aug 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

    First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to date in this clinical trialRECCE® 327 (R327) tested at four fast IV infusion times (15-mins, 20-mins, 30-mins, 45-mins) over various dosage levelsMinimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples, a dose optimization exercise for regulatory purposes SYDNEY, Australia, May 17, 2024 (G

  • GlobeNewswire

    Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study

    RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327 is being evaluated for potential use to treat ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) SYDNEY, Australia, May 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a precli

  • GlobeNewswire

    Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives

    SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035. “We thank the China National Intellectual Property Administration for their recognition of the signific